Initial Experience With the AngioVac Venous Drainage Cannula

Angiodynamics, Inc.51 enrolled

Overview

This is a retrospective, record-based study of approximately 100 patients across up to 12 centers within the United States. All patients who have been treated with the AngioVac Venous Drainage Cannula and the Extracorporeal Circuit will be considered for study participation. Eligible subject must meet all of the inclusion criteria and none of the exclusion criteria to be considered enrolled in the study. The purpose of the study is to describe initial experience with the AngioVac Venous Drainage Cannula and the Extracorporeal Circuit.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Heart Disease

Interventions

AngioVacDEVICE

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Consecutive patients treated at each study site between February 1, 2013 and February 28, 2015 will be included. Exclusion Criteria: * Patients treated with the AngioVac venous drainage system outside of those dates.

Locations (5)

Providence St. Joseph

Burbank, California, United States

UCLA

Los Angeles, California, United States

Sanford Research

Fargo, North Dakota, United States

MUSC

Charleston, South Carolina, United States

Outcomes

Primary Outcomes

Detailing early clinical experience with the AngioVac Venous Drainage Cannula

Time frame: Experience and success is determined immediately after the procedure is completed. No subject follow up data is collected and retrospective data will be reviewed.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.